Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Published Online
on August 30, 2007

Stroke. 2007
Published online before print August 30, 2007, doi: 10.1161/STROKEAHA.107.487017
A more recent version of this article appeared on October 1, 2007
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
38/10/2652    most recent
STROKEAHA.107.487017v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Colivicchi, F.
Right arrow Articles by Caltagirone, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Colivicchi, F.
Right arrow Articles by Caltagirone, C.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*ATORVASTATIN
*HEPTANOIC ACID
*PYRROLE
Medline Plus Health Information
*Stroke
Related Collections
Right arrow Compliance/Adherence
Right arrow Secondary prevention
Right arrowRelated Article

Submitted on March 4, 2007
Accepted on April 11, 2007

Discontinuation of Statin Therapy and Clinical Outcome After Ischemic Stroke

Furio Colivicchi MD, FESC*; Andrea Bassi MD; Massimo Santini MD, FESC; and Carlo Caltagirone MD

From the Cardiovascular Department (F.C., M.S.), San Filippo Neri Hospital; IRCCS Santa Lucia Foundation (A.B., C.C.); and the Department of Neurology (C.C.), University of Rome "Tor Vergata," Rome, Italy.

* To whom correspondence should be addressed. E-mail: furcol{at}rdn.it.

Background and Purpose—The majority of patients with previous ischemic stroke are expected to benefit significantly from long-term statin therapy. However, discontinuation of medication therapy frequently occurs in clinical practice. The aim of this study was to assess the impact of discontinued statin therapy on clinical outcome in patients discharged after an acute ischemic stroke.

Methods—The study population included 631 consecutive stroke survivors (322 men and 309 women; mean±SD age, 70.2±7.6 years) without clinical evidence of coronary heart disease. All patients were discharged on statin therapy and were followed up for 12 months after the acute ischemic stroke.

Results—Within 12 months from discharge, 246 patients (38.9%) discontinued statin therapy; the mean time from discharge to statin discontinuation was 48.6±54.9 days (median time, 30 days; interquartile range, 18 to 55 days). During follow-up, 116 patients died (1-year probability of death=0.18; 95% CI, 0.15 to 0.21). Multivariate analysis demonstrated that after adjustment for all confounders and interactions, statin therapy discontinuation (hazard ratio=2.78; 95% CI, 1.96 to 3.72; P=0.003) was an independent predictor of all-cause 1-year mortality.

Conclusions—A large number of patients discontinue their use of statins early after acute stroke. Moreover, patients discontinuing statins have a significantly increased mortality during the first year after the acute cerebrovascular event. These findings suggest that patient care should be improved during the transition from a hospital setting to outpatient primary care.


Key words: adherence • statins • stroke


Related Article:

Do We Need to Assess the Effect of Treatment Withdrawal?: The Paradigm of Life-Long Prevention
François Gueyffier and Théodora Bejan-Angoulvant
Stroke 2007 38: 2629-2630. [Full Text] [PDF]



This article has been cited by other articles:


Home page
J. Am. Soc. Nephrol.Home page
E. Ritz and C. Wanner
Lipid Abnormalities and Cardiovascular Risk in Renal Disease
J. Am. Soc. Nephrol., June 1, 2008; 19(6): 1065 - 1070.
[Abstract] [Full Text] [PDF]